In a study by Toker et al., ovarian cancer tumor infiltrating Tregs exhibited a highly activated phenotype distinct from Tregs in melanoma, a cancer with exceptionally high response rates to PD-1 therapy. The gene discussed is PDCD1; the disease is ovarian cancer.